Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
C12orf75 antisense RNA 1 (C12orf75-AS1) is a long non-coding RNA found on chromosome 12 (12q23.3), frequently referenced as KCCAT198 and associated with renal cell carcinoma, particularly the clear cell subtype[5]. Like other antisense RNAs, C12orf75-AS1 is presumed to regulate gene expression by hybridizing to sense transcripts, possibly influencing cell migration, invasion, and tumor progression indirectly[11]. While C12orf75-AS1 has been identified as a potential cancer biomarker, no drugs directly target it. Its precise function, mechanisms, and clinical significance are still being elucidated in the context of non-coding RNA research[5][7][8][11]. If you seek structured data for database import, these guidelines will apply. If you need mapping to protein-coding entities, note that C12orf75-AS1 is distinct from C12orf75 (OCC-1, Overexpressed in colon carcinoma-1)[3][5].
Not applicable for approved drugs. In principle, antisense RNA molecules act by hybridizing to complementary mRNA, interfering with translation or mRNA stability—an approach used in research and sometimes in therapeutic oligonucleotide development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on C12orf75 antisense RNA 1 (C12orf75-AS1).